SOUTH SAN FRANCISCO, CA, Neuron23, an early stage biotechnology company, has closed a $100 million Series C financing.
Neuron23 Inc., an early stage biotechnology company focused on developing precision medicines for genetically defined neurological and immunological diseases, has closed a $100 million Series C financing round led by SoftBank Vision Fund 2, bringing the company's total financing raised to date to $213.5 million.
Neuron23's Series A and B investors - Westlake Village BioPartners, Kleiner Perkins, Redmile Group, Cowen Healthcare Investments, Acorn Bioventures, HBM Partners, Perceptive Advisors, and Surveyor Capital (a Citadel company) - also participated in the Series C financing round.
(c) by Massinvestor, Inc. For contact info, please check out our
about page.
